Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA has completed a private placement of 23,148,148 new shares, raising approximately NOK 250 million, and is preparing a subsequent offering of up to 7,638,888 additional shares at NOK 10.80 each. The repair offering will be directed at eligible existing shareholders as of 7 April 2026 who did not participate in the placement and is subject to a national prospectus, market conditions and potential cancellation if the share price trades below the offer level.
The planned subsequent offering underscores Circio’s effort to strengthen its capital base as it advances its circular RNA-based gene and cell therapy platform. By giving non-participating shareholders a chance to subscribe on the same terms as the private placement, the company seeks to balance funding needs with shareholder inclusion, while retaining flexibility to adjust or cancel the transaction depending on market demand and pricing.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing circular RNA expression technology for gene and cell therapies. Through its proprietary circVec platform, developed by its subsidiary Circio AB in Stockholm, the company aims to deliver longer-lasting and higher-level gene expression for applications in genetic medicine, cell therapy and chronic disease treatments.
Average Trading Volume: 10,110,733
Current Market Cap: NOK2.09B
For an in-depth examination of 0RIS stock, go to TipRanks’ Overview page.